Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zyla Life Sciences was a specialty pharmaceutical company dedicated to developing and commercializing products for patients living with pain and inflammation. The company's commercial portfolio featured several FDA-approved treatments, including Sprix Nasal Spray, Indocin (indomethacin) suppositories and oral suspension, and the SoluMatrix-based products Vivlodex and Zorvolex. Zyla emerged from the restructuring of Egalet Corporation with a focus on providing non-opioid and abuse-deterrent therapeutic options. The company utilized its proprietary Guardian Technology to create tablets that are difficult to manipulate for misuse. In May 2020, Zyla was acquired by Assertio Therapeutics in an all-stock transaction to create a more robust specialty pharmaceutical entity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zyla Life Sciences.